Publications
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study.
Lymphocyte development and lymphoid disorders, Front Immunol Dec 8, 2022
Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation.
Immune responses in the immunocompromised host, Blood Dec 8, 2022
Applications of Non-Coding RNAs in Multiple Myeloma Patients.
Lymphocyte development and lymphoid disorders, Clinical Applications of Non-Coding RNAs in Cancer Dec 7, 2022
Milestones in acute GVHD pathophysiology.
Immune responses in the immunocompromised host, Front Immunol Dec 5, 2022
Toward practical transparent verifiable and long-term reproducible research using Guix.
Immune responses in the immunocompromised host, Sci Data Oct 4, 2022
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.
Immune responses in the immunocompromised host, Blood Adv. Aug 9, 2022
Context-Dependent Effects Explain Divergent Prognostic Roles of Tregs in Cancer
Human Systems Immunology & Inflammatory Networks, Cancers Jul 17, 2022
Biodistribution of allogenic umbilical cord-derived mesenchymal stromal cells after fetal repair of myelomeningocele in an ovine model
Stem cells biotechnologies, Stem Cell Res Ther. Jul 15, 2022
CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment.
Lymphocyte development and lymphoid disorders, EJHaem Jun 21, 2022